Radioprotección en radioyodoterapia para cáncer tiroideo

Autores/as

  • Jaime Carmona C. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección Medicina Nuclear
  • Juan Pablo Zhindon P. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección Medicina Nuclear
  • Javiera González A. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección Medicina Nuclear
  • René Fernández B., Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección Medicina Nuclear
  • Patricio González E. jpzhindon@hcuch.cl

Resumen

Radioiodine therapy is a widely useful tool used in adjuvant treatment for differentiated thyroid cancer and has proven beneficial effect. Is crucial to safeguard and prevent caregivers, medical staff and the general public from the patients treated with I-131 in order to minimize radiation exposure and avoid unnecessary irradiation. There are many guidelines recomendations (ATA, EANM) that are helpful for the prevention, minimize of exposure and possible contamination from the patient. The aim of this study is to provide radiation protection measures used in radioiodine therapy order to avoid contamination of the patient and his environment.

Palabras clave:

Radioisótopos de Yodo, Neoplasias de la Tiroides/radioterapia, Protección Radiológica, Radiación Ionizante